Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $340.56 Consensus Price Target from Brokerages

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have earned an average rating of “Moderate Buy” from the twelve brokerages that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $340.5556.

A number of equities analysts recently issued reports on KRYS shares. Weiss Ratings cut Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, July 1st. Evercore reaffirmed an “outperform” rating and set a $300.00 target price on shares of Krystal Biotech in a report on Tuesday, May 5th. TD Cowen increased their price target on Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Citigroup lifted their price target on Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Finally, Wolfe Research assumed coverage on Krystal Biotech in a report on Friday, March 27th. They set a “peer perform” rating on the stock.

Insider Activity

In other news, EVP John Charles Thomas sold 1,000 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the completion of the sale, the executive vice president owned 1,000 shares in the company, valued at $347,270. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the sale, the insider directly owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. This trade represents a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 26,642 shares of company stock valued at $8,243,923. Corporate insiders own 13.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

Several hedge funds have recently bought and sold shares of KRYS. Western Wealth Management LLC acquired a new stake in Krystal Biotech during the 1st quarter worth about $34,000. Greenline Wealth Management LLC purchased a new stake in shares of Krystal Biotech in the fourth quarter worth approximately $34,000. Sound Income Strategies LLC lifted its position in shares of Krystal Biotech by 1,270.0% in the fourth quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after purchasing an additional 127 shares in the last quarter. UMB Bank n.a. boosted its holdings in shares of Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after purchasing an additional 37 shares during the period. Finally, Global Retirement Partners LLC boosted its holdings in shares of Krystal Biotech by 788.9% during the fourth quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock worth $39,000 after purchasing an additional 142 shares during the period. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Price Performance

NASDAQ KRYS opened at $371.24 on Friday. Krystal Biotech has a 12 month low of $130.50 and a 12 month high of $382.54. The company has a market capitalization of $10.94 billion, a P/E ratio of 49.63 and a beta of 0.50. The company’s 50 day simple moving average is $323.03 and its 200 day simple moving average is $285.47.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, topping analysts’ consensus estimates of $1.45 by $0.38. The firm had revenue of $116.36 million during the quarter, compared to analysts’ expectations of $112.11 million. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. On average, analysts anticipate that Krystal Biotech will post 7.66 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.